Published in Schizophr Res on February 23, 2007
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull (2008) 1.70
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol (2009) 1.44
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull (2011) 0.91
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology (2010) 0.83
Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology (2011) 0.79
A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci (2009) 0.77
Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine. ISRN Psychiatry (2014) 0.75
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry (2017) 0.75
Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review. CADTH Technol Overv (2012) 0.75
Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study. Psychiatry Investig (2016) 0.75
Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. Psychopharmacology (Berl) (2010) 0.75
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry (2010) 2.45
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry (2005) 2.35
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol (2005) 2.07
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry (2005) 1.91
Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia. Schizophr Res (2005) 1.90
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol (2007) 1.66
Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry (2004) 1.65
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry (2005) 1.61
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation? Biol Psychiatry (2011) 1.52
Extinction memory is impaired in schizophrenia. Biol Psychiatry (2008) 1.50
Reduced error-related activation in two anterior cingulate circuits is related to impaired performance in schizophrenia. Brain (2007) 1.49
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol (2009) 1.49
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol (2009) 1.44
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry (2004) 1.41
Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation. Acad Psychiatry (2013) 1.40
Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol (2005) 1.40
A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry (2007) 1.39
Catatonic coma with profound bradycardia. Psychosomatics (2007) 1.38
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proc Natl Acad Sci U S A (2008) 1.30
Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biol Psychiatry (2003) 1.29
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res (2005) 1.28
Sustained activation of the hippocampus in response to fearful faces in schizophrenia. Biol Psychiatry (2005) 1.23
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry (2004) 1.22
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry (2009) 1.20
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
An anterior-to-posterior shift in midline cortical activity in schizophrenia during self-reflection. Biol Psychiatry (2010) 1.16
Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry (2006) 1.14
SEMAPHORE1 functions during the regulation of ancestrally duplicated knox genes and polar auxin transport in maize. Development (2002) 1.13
Developing novel treatments for mood disorders: accelerating discovery. Biol Psychiatry (2002) 1.13
Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks. Biol Psychiatry (2002) 1.10
Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2008) 1.10
Reduced microstructural integrity of the white matter underlying anterior cingulate cortex is associated with increased saccadic latency in schizophrenia. Neuroimage (2007) 1.10
Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. Harv Rev Psychiatry (2006) 1.09
Anterior cingulate cortex activation during cognitive interference in schizophrenia. Am J Psychiatry (2004) 1.08
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol (2008) 1.08
Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord (2002) 1.08
Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry (2007) 1.07
Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res (2007) 1.07
A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia. Biol Psychiatry (2004) 1.06
Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry (2008) 1.06
Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. J Psychiatr Res (2009) 1.04
Prevalence and predictors of posttraumatic stress disorder and depression in HIV-infected and at-risk Rwandan women. J Womens Health (Larchmt) (2009) 1.04
Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res (2006) 1.04
Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry (2007) 1.04
Capacity building in global mental health: professional training. Harv Rev Psychiatry (2012) 1.04
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res (2011) 1.03
A pilot study of functional Cognitive Behavioral Therapy (fCBT) for schizophrenia. Schizophr Res (2005) 1.03
Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res (2010) 1.03
Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry (2013) 1.02
The misattribution of salience in delusional patients with schizophrenia. Schizophr Res (2006) 1.02
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry (2005) 1.02
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) (2004) 1.01
Inflammation and schizophrenia. Expert Rev Neurother (2007) 1.01
Dysfunction of a cortical midline network during emotional appraisals in schizophrenia. Schizophr Bull (2009) 1.00
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry (2004) 0.99
Failure of neural responses to safety cues in schizophrenia. Arch Gen Psychiatry (2012) 0.99
Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv (2006) 0.98
Motor cortical excitability in schizophrenia. Biol Psychiatry (2002) 0.98
D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res (2002) 0.97
Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry (2008) 0.97
Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn (2012) 0.97
Schizophrenia patients show intact immediate error-related performance adjustments on an antisaccade task. Schizophr Res (2006) 0.96
Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res (2011) 0.96
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry (2005) 0.96
Knowledge, attitudes, and beliefs regarding HPV vaccination: ethnic and cultural differences between African-American and Haitian immigrant women. Womens Health Issues (2012) 0.95
Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Res (2008) 0.95
Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia. J Clin Psychiatry (2010) 0.94
No physical health without mental health: lessons unlearned? Bull World Health Organ (2013) 0.93
Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res (2005) 0.93
A hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS One (2011) 0.93
Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatr Serv (2011) 0.92